A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
about
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
description
clinical trial
@en
klinisch onderzoek
@nl
name
A Phase 2 Study of Osimertinib ...... vanced EGFR Mutant Lung Cancer
@en
type
label
A Phase 2 Study of Osimertinib ...... vanced EGFR Mutant Lung Cancer
@en
prefLabel
A Phase 2 Study of Osimertinib ...... vanced EGFR Mutant Lung Cancer
@en
P6153
P1476
A Phase 2 Study of Osimertinib ...... vanced EGFR Mutant Lung Cancer
@en
P3098
NCT03392246
P4844
P580
2018-01-31T00:00:00Z
P582
2021-06-30T00:00:00Z